カルナバイオサイエンスの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2020/12/16 | 1,297 | 1,297 | 1,242 | 1,246 | -26 | -2% | 75,100 |
2020/12/15 | 1,287 | 1,291 | 1,260 | 1,272 | -28 | -2.2% | 78,300 |
2020/12/14 | 1,290 | 1,325 | 1,281 | 1,300 | +10 | +0.8% | 76,400 |
2020/12/11 | 1,305 | 1,326 | 1,280 | 1,290 | -30 | -2.3% | 157,100 |
2020/12/10 | 1,365 | 1,365 | 1,320 | 1,320 | -30 | -2.2% | 97,600 |
2020/12/09 | 1,420 | 1,420 | 1,342 | 1,350 | -49 | -3.5% | 140,200 |
2020/12/08 | 1,400 | 1,422 | 1,384 | 1,399 | -5 | -0.4% | 74,700 |
2020/12/07 | 1,400 | 1,417 | 1,390 | 1,404 | +13 | +0.9% | 125,100 |
2020/12/04 | 1,365 | 1,396 | 1,357 | 1,391 | +24 | +1.8% | 86,700 |
2020/12/03 | 1,355 | 1,386 | 1,335 | 1,367 | +15 | +1.1% | 185,400 |
2020/12/02 | 1,310 | 1,367 | 1,295 | 1,352 | +46 | +3.5% | 173,500 |
2020/12/01 | 1,278 | 1,309 | 1,260 | 1,306 | +37 | +2.9% | 99,200 |
2020/11/30 | 1,268 | 1,278 | 1,255 | 1,269 | -2 | -0.2% | 86,100 |
2020/11/27 | 1,245 | 1,284 | 1,245 | 1,271 | +27 | +2.2% | 92,800 |
2020/11/26 | 1,217 | 1,254 | 1,217 | 1,244 | +22 | +1.8% | 57,300 |
2020/11/25 | 1,244 | 1,266 | 1,217 | 1,222 | -22 | -1.8% | 86,100 |
2020/11/24 | 1,239 | 1,260 | 1,223 | 1,244 | +14 | +1.1% | 92,100 |
2020/11/20 | 1,216 | 1,233 | 1,208 | 1,230 | +3 | +0.2% | 54,400 |
2020/11/19 | 1,230 | 1,240 | 1,216 | 1,227 | -30 | -2.4% | 77,600 |
2020/11/18 | 1,225 | 1,259 | 1,225 | 1,257 | +23 | +1.9% | 57,700 |
2020/11/17 | 1,274 | 1,274 | 1,227 | 1,234 | -37 | -2.9% | 88,000 |
2020/11/16 | 1,251 | 1,286 | 1,228 | 1,271 | +13 | +1% | 144,900 |
2020/11/13 | 1,248 | 1,302 | 1,233 | 1,258 | +6 | +0.5% | 116,000 |
2020/11/12 | 1,290 | 1,294 | 1,245 | 1,252 | -38 | -2.9% | 83,800 |
2020/11/11 | 1,254 | 1,305 | 1,249 | 1,290 | +36 | +2.9% | 123,200 |
2020/11/10 | 1,240 | 1,267 | 1,204 | 1,254 | +21 | +1.7% | 142,200 |
2020/11/09 | 1,228 | 1,236 | 1,213 | 1,233 | +5 | +0.4% | 75,000 |
2020/11/06 | 1,238 | 1,256 | 1,227 | 1,228 | -21 | -1.7% | 89,500 |
2020/11/05 | 1,206 | 1,256 | 1,206 | 1,249 | +33 | +2.7% | 121,100 |
2020/11/04 | 1,206 | 1,223 | 1,187 | 1,216 | +32 | +2.7% | 78,500 |
2020/11/02 | 1,155 | 1,184 | 1,142 | 1,184 | +29 | +2.5% | 92,200 |
2020/10/30 | 1,220 | 1,220 | 1,142 | 1,155 | -61 | -5% | 187,400 |
2020/10/29 | 1,207 | 1,224 | 1,177 | 1,216 | -21 | -1.7% | 178,300 |
2020/10/28 | 1,240 | 1,269 | 1,230 | 1,237 | +10 | +0.8% | 91,600 |
2020/10/27 | 1,234 | 1,256 | 1,220 | 1,227 | -15 | -1.2% | 90,900 |
2020/10/26 | 1,242 | 1,260 | 1,231 | 1,242 | -15 | -1.2% | 144,500 |
2020/10/23 | 1,247 | 1,265 | 1,215 | 1,257 | ±0 | ±0% | 171,300 |
2020/10/22 | 1,301 | 1,304 | 1,235 | 1,257 | -49 | -3.8% | 196,300 |
2020/10/21 | 1,305 | 1,328 | 1,300 | 1,306 | +12 | +0.9% | 178,600 |
2020/10/20 | 1,318 | 1,321 | 1,291 | 1,294 | -50 | -3.7% | 117,300 |
2020/10/19 | 1,285 | 1,349 | 1,285 | 1,344 | +30 | +2.3% | 326,200 |
2020/10/16 | 1,358 | 1,358 | 1,299 | 1,314 | -44 | -3.2% | 174,700 |
2020/10/15 | 1,421 | 1,421 | 1,347 | 1,358 | -69 | -4.8% | 200,500 |
2020/10/14 | 1,461 | 1,481 | 1,425 | 1,427 | -47 | -3.2% | 98,500 |
2020/10/13 | 1,450 | 1,480 | 1,448 | 1,474 | +19 | +1.3% | 67,400 |
2020/10/12 | 1,490 | 1,490 | 1,451 | 1,455 | -8 | -0.5% | 33,800 |
2020/10/09 | 1,431 | 1,468 | 1,421 | 1,463 | +23 | +1.6% | 59,000 |
2020/10/08 | 1,465 | 1,469 | 1,435 | 1,440 | -24 | -1.6% | 77,000 |
2020/10/07 | 1,474 | 1,486 | 1,461 | 1,464 | -35 | -2.3% | 51,700 |
2020/10/06 | 1,500 | 1,512 | 1,470 | 1,499 | +10 | +0.7% | 51,300 |
951~
1000
件表示中 / 3572件
類似銘柄と比較する
現在ご覧いただいている「カルナバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
カルナバイオ | 30,400円 | -43.1% | - | 0.00% | - | 1.81倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
カイオム | 9,900円 | +2.6% | - | 0.00% | - | 5.73倍 |
|
独自の抗体作製技術を持つ理研発の創薬ベンチャー。医薬品候補抗体導出と技術供与が収益源 |
VIS | 91,000円 | +87.8% | +265.7% | 0.00% | 54.65倍 | 2.51倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
クリングル | 82,300円 | +14.5% | - | 0.00% | - | 2.43倍 |
|
細胞の増殖、保護、修復などの機能があるHGFタンパク質を用いて、難治性疾患治療薬を開発 |
DELTA-P | 65,800円 | - | - | 0.00% | - | 4.40倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
市場注目の銘柄
チャート関連のコラム